Clinical Brain Disorders Branch (CBDB), National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Bethesda, MD, USA.
CNS Drugs. 2013 Aug;27(8):663-73. doi: 10.1007/s40263-013-0082-x.
Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O-methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC.
In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task.
We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083).
The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009.
Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated.
Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH.
Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors.
There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing).
Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.
注意力是通过选择和整合相关的上下文信息,灵活地将行为和思维导向目标的能力。背侧扣带(dCC)和前额叶(PFC)皮质在注意力中起着关键作用。有证据表明,儿茶酚-O-甲基转移酶(COMT)调节 PFC 和 dCC 中的多巴胺能张力。
在这项研究中,我们探讨了托卡朋(一种穿透中枢神经系统的 COMT 抑制剂,可增加皮质多巴胺水平)对可变注意控制(VAC)任务期间大脑活动的影响。
我们进行了一项双盲、安慰剂对照、平衡试验,使用托卡朋(Tasmar,片剂,每天 3 次,每次 100mg,持续 1 天,然后每天 3 次,每次 200mg,持续 6 天;ClinicalTrials.gov 标识符:NCT00044083)。
该研究于 2005 年至 2009 年在国家心理健康研究所临床中心进行。
20 名健康志愿者(11 名男性;平均年龄=32.7 岁),在研究的两个臂均具有良好的成像和表现数据。
参与者接受了 3T 血氧水平依赖性(BOLD)功能磁共振成像(fMRI),同时执行与事件相关的 VAC 任务,该任务在三个负荷水平上改变注意力:低、中(中间)和高。
使用方差分析(ANOVA)分析行为数据和个体对比图像,药物和任务负荷为协变量。
任务负荷增加有显著的主要影响,导致准确性降低和反应时间增加。虽然托卡朋对这些行为测量没有显著影响,但神经影像学数据显示 dCC 与负荷相关的变化有显著影响,与安慰剂相比,托卡朋的 dCC 激活明显降低。此外,dCC 中的神经活动与 COMT 酶活性呈正相关(即,较低的 COMT 活性和推测的更多多巴胺与 dCC 中的较低激活相关,即信息处理效率更高)。
我们的结果表明,COMT 活性的药理学降低调节了注意力机制的参与,选择性地增强了健康志愿者中 dCC 处理的效率,表现为相同水平的性能下活动减少。